Cancer Clinical Trials Results
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paciltaxel Alone or in Combination with Bevacizumab followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum- Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer
||Fairview, Hillcrest, Main Campus|| ||Phase 3||Gynecologic, Ovarian
|GOG 0225||IRB 12-869||
Can Diet and Physical Activity Modulate Ovarian or Primary Peritoneal Cancer Progression-Free Survival?
||Fairview, Hillcrest, Main Campus|| || ||Gynecologic, Ovarian, Peritoneal
A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advance Stage and Recurrent Chemo-Naive Sex Cord-Stromal Tumors of the Ovary
||Fairview, Hillcrest, Main Campus||Stage 2, Stage 3, Stage 4||Phase 2||Gynecologic, Ovarian
MORAb-003-011, A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer
||Main Campus|| ||Phase 2||Gynecologic, Ovarian
Cancer Answers & Appointments
Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.
Monday through Friday from 8 a.m. – 4:30 p.m. (ET).
Resources for medical professionals
- Outpatient appointment referrals: 216.444.7923 or 866.223.8100
- Inpatient hospital transfers: 800.553.5056
- Referring Physician Concierge: 216.444.6196 or 216.312.4910.
Search available cancer clinical trials by disease, hospital, phase or number.
This information is provided by Cleveland Clinic and is not intended to replace
the medical advice of your doctor or health care provider.
Please consult your health care provider for advice about a specific medical condition.
© Copyright 2015 Cleveland Clinic. All rights reserved.